Compounds > enzastaurin
Page last updated: 2024-09-05

enzastaurin and vx680

enzastaurin has been researched along with vx680 in 4 studies

Compound Research Comparison

Studies
(enzastaurin)		Trials
(enzastaurin)		Recent Studies (post-2010)
(enzastaurin)		Studies
(vx680)		Trials
(vx680)		Recent Studies (post-2010) (vx680)
18852992273143

Protein Interaction Comparison

ProteinTaxonomyenzastaurin (IC50)vx680 (IC50)
Aurora kinase AHomo sapiens (human)0.1805
Tyrosine-protein kinase ABL1Homo sapiens (human)0.4538
Tyrosine-protein kinase ABL1Mus musculus (house mouse)5
Proto-oncogene tyrosine-protein kinase SrcGallus gallus (chicken)0.34
Cyclin-dependent kinase 1Homo sapiens (human)0.4432
Insulin-like growth factor 1 receptorHomo sapiens (human)0.5
Beta-1 adrenergic receptorHomo sapiens (human)0.055
Breakpoint cluster region proteinHomo sapiens (human)0.0501
Cyclin-dependent kinase 4Homo sapiens (human)0.0006
G2/mitotic-specific cyclin-B1Homo sapiens (human)0.0092
G1/S-specific cyclin-D1Homo sapiens (human)0.0006
Cyclin-dependent kinase 2Homo sapiens (human)0.4974
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.03
Serine/threonine-protein kinase PLK1Homo sapiens (human)0.4974
Aurora kinase AMus musculus (house mouse)0.0006
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.208
Maternal embryonic leucine zipper kinaseHomo sapiens (human)0.42
Discoidin domain-containing receptor 2Homo sapiens (human)0.1295
Receptor-interacting serine/threonine-protein kinase 1 Mus musculus (house mouse)1
Aurora kinase B-AXenopus laevis (African clawed frog)0.019
Aurora kinase BHomo sapiens (human)0.2175
Serine/threonine-protein kinase TBK1Homo sapiens (human)3.1131
Aurora kinase CHomo sapiens (human)0.3516

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Alaoui-Jamali, MA; Amzil, H; Bijian, K; Lim, FPL; Miron, CE; Moitessier, N; Nivedha, AK; Su, J; Wernic, D1

Other Studies

4 other study(ies) available for enzastaurin and vx680

ArticleYear
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
Novel Aurora A and Protein Kinase C (α, β1, β2, and θ) Multitarget Inhibitors: Impact of Selenium Atoms on the Potency and Selectivity.
    Journal of medicinal chemistry, 2022, 02-24, Volume: 65, Issue:4

    Topics: Antineoplastic Agents; Aurora Kinase A; Breast Neoplasms; Cell Line, Tumor; Drug Screening Assays, Antitumor; Female; Humans; Hydrogen Bonding; Isoenzymes; Molecular Docking Simulation; Protein Kinase C; Protein Kinase Inhibitors; Selenium Compounds; Small Molecule Libraries; Structure-Activity Relationship; Substrate Specificity; Tumor Stem Cell Assay

2022